Alexander disease
Methodology & AI Transparency ⓘ
Alexander disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Alexander disease (ICD-10-CM G31.86), Alzheimer, Dementia & Memory Health protocols prioritize hearing/vision optimization [Alexander disease G31.86] paired with baseline and interval Homocysteine & Vitamin in Alexander disease (G31.86: B12) assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code G31.86 categorizes Alexander disease under Alzheimer, Dementia & Memory Health.
- 3 Typical cash cost range: Workup highlights for Alexander disease (G31.86): hearing/vision optimization [Alexander disease G31.86].
- 4 Top reported side effects / signs: Key Memory & Cognition biomarkers for Alexander disease (G31.86): Homocysteine & Vitamin in Alexander disease (G31.86: B12) & TSH & Fasting in Alexander disease (G31.86: ApoB / HbA1c) (Optimal cardiometabolic neuroprotection (G31.86)).
Ask our AI Specialists anything about Alexander disease
What Is Alexander disease?
For patients presenting with Alexander disease (ICD-10-CM G31.86), Alzheimer, Dementia & Memory Health protocols prioritize hearing/vision optimization [Alexander disease G31.86] paired with baseline and interval Homocysteine & Vitamin in Alexander disease (G31.86: B12) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Alexander disease (G31.86, Memory & Cognition) reflects cerebral small-vessel microvascular in Alexander disease (G31.86: hypoperfusion). longitudinal control is benchmarked via Homocysteine & Vitamin in Alexander disease (G31.86: B12).
Common Symptoms & Clinical Signs
- • Presentation of Alexander disease (G31.86): short-term recall difficulty in Alexander disease (G31.86: for recent conversations,)
- • Secondary Alexander disease clinical sign: word-finding pauses, difficulty in Alexander disease (G31.86: managing multi-step finances,)
- • Symptom flares in Alexander disease correlating with Homocysteine & Vitamin in Alexander disease (G31.86: B12) deviation outside Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.86)
- • Functional memory & cognition impact requiring hearing/vision optimization [Alexander disease G31.86] evaluation (G31.86)
Alexander disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G31.86 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Alexander disease (G31.86: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.86) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Alexander disease (G31.86: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G31.86) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Alexander disease (G31.86: Score) | >= 26 / 30 (G31.86) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Alexander disease
Treatment selection for Alexander disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Alexander disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate The measurements used for the assessment of apathy in patients with AD had a high degree of overlap with the DCA. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 32565008 ↗ |
| Can This Approach Help? Inside the Latest Research on Japanese participant data from three gantenerumab trials in early Alzheimer's Slowing of cognitive and functional decline, and amyloid reduction in gantenerumab group compared to placebo group were greater in Japanese-GRADUATE than in the global-GRADUATE and JP40959. Alzheimer's & dementia : the journal of the Alzheimer's Association • 2025-04-15 • Phase III Randomized Trial | N = 132 | 88/100 | PMID 40302041 ↗ |
| New Insights on Differences in Cognitive Aging Assessments Associated With Retest: What a 977-Participant Study Found A total of 977 older adults (mean [SD] baseline age, 76.3 [4.0] years; 523 [54%] female) contributed 2571 in-person cognitive assessments , including 552 adults (57%) with mild hearing loss and 739 adults (76%) recruited de novo. JAMA network open • 2026-08-03 • Phase III Randomized Trial | N = 977 | 87/100 | PMID 42584890 ↗ |
Alexander disease Patient Community & “People Like Me” Threads
Filter Alexander disease community threads and patient logs by age, biological sex, dosage, and treatment duration.